Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects
NCT ID: NCT05106205
Last Updated: 2022-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2021-12-21
2022-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State
NCT05098262
Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State
NCT05098275
Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fasting State
NCT05108571
The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults
NCT05321732
Pharmacokinetics and Safety of DWJ1451 in Healthy Adults
NCT04819932
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence A
DA-5213 10mg
single dose administration (one tablet once a day)
DA-5213-R 10mg
single dose administration (one tablet once a day)
Sequence B
DA-5213 10mg
single dose administration (one tablet once a day)
DA-5213-R 10mg
single dose administration (one tablet once a day)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DA-5213 10mg
single dose administration (one tablet once a day)
DA-5213-R 10mg
single dose administration (one tablet once a day)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 18.0 and 30.0 kg/m2
* Body weight : Male≥50kg, Female≥45kg
Exclusion Criteria
* Clinically significant Medical History
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dong-A ST Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Hospital
Siheung-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BIBE2021-55
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.